natgillin/translations-raw huggingface dataset:
A compound of any one of claims 1-7, or a pharmaceutically acceptable salt thereof, for use in inhibiting growth of a cell transformed by a virus, wherein the virus is selected from the group consisting of human papilloma virus, HIV, hepatitis B virus, hepatitis C virus, variola virus, vaccinia virus, an adenovirus, a cytomegalovirus, herpes simplex virus 1, herpes simplex virus 2, Epstein Barr virus, BK virus, JC virus, cervical intraepithelial neoplasia, anal intraepithelial neoplasia, and vulvar intraepithelial neoplasia, feline leukemia virus and feline immunodeficiency virus. 
Spoj prema bilo kojem zahtjevu od 1 do 7, ili njegova farmaceutski prihvatljiva sol, za primjenu u inhibiciji rasta ćelija koje je transformirao virus, naznačen time, što je virus odabran iz skupine koja se sastoji od ljudskog papilomavorusa, HIV-a, virusa hepatitisa B, virusa hepatitisa C, virusa boginja, virusa kravljih boginja, adenovirusa, citomegalovirusa, virusa herpesa simpleksa 1, virusa herpesa simpleksa 2, Epstein Barrovog virusa, BK virusa, JC virusa, cervikalne intraepitelne neoplazije, analne intraepitelne neoplazije i vulvarne intraepitelne neoplazije, virusa mačje leukemije i virusa mačje imunodeficijencije.
The pharmaceutical composition of claim 15 for use in treating a viral disease in a subject, wherein the viral disease is selected from the group consisting of human papilloma virus, hepatitis B virus, variola virus, vaccinia virus, an adenovirus, a cytomegalovirus, herpes simplex virus 1, herpes simplex virus 2, Epstein Barr virus, BK virus, JC virus, cervical intraepithelial neoplasia, anal intraepithelial neoplasia, and vulvar intraepithelial neoplasia. 
Farmaceutski pripravak prema zahtjevu 15 za primjenu u liječenju virusnog oboljenja kod ispitanika, naznačen time, što je virusno oboljenje odabrano iz skupine koja se sastoji od ljudskog papilomavorusa, virusa hepatitisa B, virusa boginja, virusa kravljih boginja, adenovirusa, citomegalovirusa, virusa herpesa simpleksa 1, virusa herpesa simpleksa 2, Epstein Barrovog virusa, BK virusa, JC virusa, cervikalne intraepitelne neoplazije, analne intraepitelne neoplazije i vulvarne intraepitelne neoplazije.
The pharmaceutical composition of claim 8 or claim 15, suitable for a topical dosage form. 
Farmaceutski pripravak prema zahtjevu 8 ili zahtjevu 15, prikladan za upotrebu u obliku topikalne doze.
The pharmaceutical composition of claim 8 or claim 15, suitable for an oral dosage form. 
Farmaceutski pripravak prema zahtjevu 8 ili 15, prikladan za upotrebu u obliku oralne doze.
A beverage vending machine, characterized by comprising a device for feeding cups (18, 19) according to any one of claims 1 to 5 or a device for feeding cups that operates according to a method of claim 6 or 7. 
Stroj za prodaju napitaka, naznačen time, da sadrži aparat za dodavanje čaša (18, 19) prema bilo kojem od patentnih zahtjeva 1 do 5 ili aparat za dodavanje čaša koji radi prema postupku iz patentnih zahtjeva 6 ili 7.
A compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein; 
Spoj formule (I) ili farmaceutski prihvatljiva sol istog, pri čemu;
The compound according to claim 1 or pharmaceutically acceptable salt thereof, wherein R1 is methyl. 
Spoj opisan u točki 1 patentnog zahtjeva ili farmaceutski prihvatljiva sol istoga, pri čemu je R1 metil.
The compound according to claim 1 or pharmaceutically acceptable salt thereof, wherein R4 is optionally substituted phenyl. 
Spoj opisan u točki 1 patentnog zahtjeva ili farmaceutski prihvatljiva sol istoga, pri čemu je R4 opcionalno supstituirani fenil.
The compound according to claim 1 or pharmaceutically acceptable salt thereof, wherein R4 is 2,5-dimethyl-1H-pyrrole. 
Spoj opisan u točki 1 patentnog zahtjeva ili farmaceutski prihvatljiva sol istoga, pri čemu je R4 2,5-dimetil-1H-pirol.
The compound according to claim 1 or pharmaceutically acceptable salt thereof, wherein R3 is hydroxy. 
Spoj opisan u točki 1 patentnog zahtjeva ili farmaceutski prihvatljiva sol istoga, pri čemu je R3 hidroksi.
The compound according to claim 1 or pharmaceutically acceptable salt thereof, wherein the compound is a compound of formula (1b) wherein the dotted line [---], R1, R3 and R4 are same as described in claim 1. 
Spoj opisan u točki 1 patentnog zahtjeva ili farmaceutski prihvatljiva sol istoga, pri čemu je spoj spoj iz formule (1b) Pri čemu su istočkana crta [....], R1, R3 i R4 opisani u točki 1.
The compound according to claim 1, wherein the compound is selected from the group consisting of 
Spoj opisan u točki 1, pri čemu je spoj odabran iz grupe koja se sastoji od:
The compound according to claim 1, wherein the compound is a compound of the following structural formula or a pharmaceutically acceptable salt thereof. 
Spoj opisan u točki 1 patentnog zahtjeva, pri čemu je spoj spoj sljedeće strukturalne formule ili farmaceutski prihvatljiva sol istoga.
A compound according to any one of claims 1-15, or a pharmaceutically acceptable salt thereof, for use in treatment or prophylaxis of multiple sclerosis or rheumatoid arthritis. 
Spoj prema opisu bilo koje točke 1-15 patentnog zahtjeva ili farmaceutski prihvatljiva sol istoga za upotrebu kao lijek ili profilaksa u liječenju multiple skleroze ili reumatoidnog artritisa.
A compound according to any one of claims 1-15 or a pharmaceutically acceptable salt thereof, for use in treatment and prophylaxis of cancer diseases, inflammatory bowel disease or rheumatoid arthritis. 
Spoj prema opisu bilo koje točke 1-15 patentnog zahtjeva ili farmaceutski prihvatljiva sol istoga za upotrebu kao lijek ili profilaksa kod bolesti raka, upalne crijevne bolesti ili reumatoidnog artritisa.
The vector of any one of claims 1-2, wherein the vector comprises a mutation in UL128 or UL130 selected from a point mutation, a frameshift mutation, or a deletion of all or less than all of UL128 or UL130; and/or further comprising a fourth nucleic acid sequence, wherein the fourth nucleic acid sequence comprises an antisense sequence or an RNAi sequence that inhibits the expression of UL128 or UL130. 
Vektor u skladu s bilo kojim od patentnih zahtjeva 1 do 2, naznačen time, da vektor sadržava mutaciju u UL128 ili UL130, odabranoj od točke mutacije, frame-shift mutaciju (pomak okvira čitanjagenetičke šifre) ili brisanja svih ili manje od svih UL128 ili UL130; i / ili nadalje sadržava četvrtu sekvencu nukleinske kiseline, pri čemu četvrta sekvenca nukleinske kiseline sadržava antisens sekvencu ili RNAi sekvencu koja inhibira ekspresiju UL128 ili UL130.
A composition for use in immunizing a subject against a pathogen-specific or cancer antigen, wherein the composition comprises a first cytomegalovirus vector comprising: 
Pripravak namijenjen upotrebi u imunizaciji subjekta protiv patogenog specifičnog ili antigena raka, naznačen time, da pripravak sadržava prvi citomegalovirusni vektor koji sadržava:
A composition for use in immunizing a subject against a pathogen-specific or cancer antigen, wherein the composition comprises a first cytomegalovirus vector comprising: 
Pripravak namijenjen upotrebi u imunizaciji subjekta protiv patogenog specifičnog ili tumorski antigen, naznačen time, da pripravak sadržava prvi citomegalovirusni vektor koji sadržava:
A method for recovering plastic from complex materials; comprising, at least, the following phases: 
Postupak ponovnog dobivanja plastike od kompleksnih materijala; sadrži barem slijedeće faze:
a first grouping into balls of the polyester fluff contained in the product obtained from the first grinding, in a drum (B1) with aspiration, 
prvo grupiranje u kuglice od poliesterskih lebdećih vlakana sadržanih u proizvodu dobivenom iz prvog mljevenja, u bubnju (B1) s aspiracijom,
a second grinding of the remaining mixture into granules of 4 to 6 millimetres in a mill (M2) with aspiration; 
drugo mljevenje preostale smjese u granule od 4 do 6 milimetara u mlinu (M2) s aspiracijom;
a second grouping into balls, in a drum (B2) with aspiration, of the polyester fluff contained in the product obtained from the second grinding; 
drugo grupiranje u kuglice, u bubnju (B2) s aspiracijom, od poliesterskih lebdećih vlakana sadržanih u proizvodu dobivenom iz drugog mljevenja;
a third grouping into balls of the polyester fluff contained in the product obtained from the third grinding in a drum (B3) with aspiration, 
treće grupiranje u kuglice od poliesterskih lebdećih vlakana sadržanih u proizvodu dobivenom iz trećeg mljevenja u bubnju (B3) s aspiracijom,
a separation by aspiration of the suspended dust contained in the product obtained from the third grinding in a hopper (TO2); 
odvajanje aspiracijom raspršene prašine sadržane u proizvodu dobivenom od trećeg mljevenja u ljevku (TO2);
removing the polyester fluff contained in the remaining mixture of plastic with polyester from the third separation by successive agitation of said remaining mixture and respective removal of the polyester fluff by sifting, aspiration, blowing and/or propulsion, until a plastic purity of 99.99% is obtained. 
uklanjanje poliesterskih lebdećih vlakana sadržanih u preostaloj smjesi plastike s poliesterom iz trećeg odvajanja sukcesivnim miješanjem navedene preostale smjese i odgovarajućim uklanjanjem poliesterskih lebdećih vlakana propuštanjem kroz sito, aspiracijom, puhanjem i/ili propulzijom, sve dok se ne dobije čistoća plastike od 99,99%.
The method, according to Claim 1, characterised in that in the steps a) - j) a removal by aspiration of the suspended dust fluff into accumulation tanks (D) is performed. 
Postupak, sukladno patentnom zahtjevu 1, naznačen time što se u koracima a) - j) provodi uklanjanje aspiracije lebdećih vlakana raspršene prašine u akumulacijske rezervoare (D).
The method, according to Claim 1, characterised in that the removal I) of the polyester fluff contained in the remaining mixture of plastic with polyester from the third separation, comprises the following steps: 
Postupak, sukladno patentnom zahtjevu 1, naznačen time što uklanjanje I) poliesterskih lebdećih vlakana sadržanih u preostaloj smjesi plastike s poliesterom iz trećeg odvajanja, sadrži slijedeće korake:
agitating the product mixture in a cyclone separator (CT1); 
miješanje smjese proizvoda u ciklonskom separatoru (CT1);
recirculating the product through a first storage silo (S1) with aspiration and with an endless agitator and through sifters (T4, T5), which separate the fluff balls formed in the endless agitator from the remaining mixture of plastic and fluff; 
recirkulirajući proizvod kroz prvi skladišni silos (S1) s aspiracijom i s beskonačnim mješalicom i kroz sita (T4, T5), koji odvajaju kuglice lebdećih vlakana nastale u beskonačnoj mješalici iz preostale smjese plastike i lebdećih vlakana;
recirculating the product through a second storage silo (S2) with aspiration and with an endless agitator and through sifters (T6, T7), which separate the fluff balls formed in the endless agitator from the remaining mixture of plastic and fluff; 
recirkulirajući proizvod kroz drugi skladišni silos (S2) s aspiracijom i s beskonačnom mješalicom i kroz sita (T6, T7), koja odvajaju kuglice lebdećih vlakana nastale u beskonačnoj mješalici od preostale smjese plastike i lebdećih vlakana;
pouring the remaining mixture of the product, in the form of curtain, into an air box (CA), which removes the fluff, and 
lijevanje preostale smjese proizvoda, u obliku zavjesa, u zračni pretinac (CA), koji uklanja lebdeća vlakna, i
removing any possible traces of fluff by passing the product through a cyclone separator (CT2), which provides the recovered plastic with a purity of 99.99%. 
uklanjanje mogućih tragova lebdećih vlakana provlačenjem proizvoda kroz ciklonski separator (CT2), koji daje oporavljenu plastiku čistoće od 99,99%.
Process for the synthesis 7,8-dimethoxy-1,3-dihydro-benzazepin-2-one of formula (II) from 3,4-dimethoxy-phenylacetic acid of formula (III) characterized by 
Postupak za sintezu 7,8-dimetoksi-1,3-dihidro-benzazepin-2-ona formule (II) iz 3,4-dimetoksi-fenil-octene kiseline formule (III) naznačen
reacting the compound of formula (III) with aminoacetaldehyde dimethyl acetal of formula (IV) in an organic solvent immiscible with water in the presence of catalytic amount of boron compound of formula BR1R2R3, wherein the meaning of R1, R2, R3 is independently of each other -OH, -OR, -OAr group or a halogen atom, wherein the meaning of R is an aliphatic group, and Ar is an optionally substituted aromatic or heteroaromatic group containing O, N, S atoms, furthermore the meaning of R1 is an optionally substituted aromatic or aliphatic group and the meaning of R2, R3 is independently of each other as given above; 
reakcijom spoja formule (III) s aminoacetaldehid dimetil acetalom formule (IV) u organskoj otopini koja se ne miješa s vodom u prisutnosti katalitičke količine spoja bora formule BR1R2R3, pri čemu je značenje R1, R2, R3 međusobno neovisno –OH, -OR, -Oar skupina ili atom halogena, pri čemu je značenje R alifatska skupina, i Ar je opcionalno zamijenjena aromatska ili heteroaromatska skupina sadržeći O, N, S atome, nadalje značenje R1 je opcionalno zamijenjena aromatska ili alifatska skupina i značenje R2, R3 je međusobno neovisno kao što je navedeno gore;
The process according to claim 2, wherein the boron catalyst is used in an amount of 5-100 mol%. 
Postupak prema zahtjevu 2, pri čemu je borov katalizator korišten u količini od 5–100 mol%.
The process according to claim 3, wherein the boron catalyst is used in an amount of 10 mol%. 
Postupak prema zahtjevu 3, pri čemu je borov katalizator korišten u količini od 10 mol%.
The process according to claim 1, wherein the anhydrous acid used in the ring-closure reaction is methanesulfonic acid. 
Postupak prema zahtjevu 1, pri čemu je bezvodna kiselina korištena u reakciji zatvaranja prstena je metansulfonska kiselina.
The process according to claim 1, wherein the amount of the anhydrous acid used in the ring-closure reaction is 3-15 fold as compared to the amount of 3,4-dimethoxy-phenylacetic acid of formula (III), preferably 7 fold. 
Postupak prema zahtjevu 1, pri čemu je količina bezvodne kiseline korištene u reakciji zatvaranja prstena 3-15 -struka u usporedbi s količinom 3,4-dimetoksi-feniloctene kiseline formule (III), poželjno 7 -struka.
Process according to claim 1 for the synthesis of a compound of formula (I) or a pharmaceutically acceptable salt thereof comprising, after i) and ii): 
Postupak prema zahtjevu 1 za sintezu spoja formule (I) ili farmaceutski prihvatljive soli istoga sadržeći, nakon i) i ii):
iii) transforming the obtained compound of formula (II) into the compound of formula (I) or an acid addition salt thereof by known methods. 
iii) pretvaranje dobivenog spoja formule (II) u spoj formule (I) ili sol kao dodatak kiselini istoga putem poznatih metoda.
A peptide effective in blocking X4 tropic HIV-1 NL4-3 infection with an IC50 value of less than 50µM having an amino acid sequence selected from the group consisting of 
Peptid učinkovit u blokiranju X4 tropne HIV-1 NL4-3 infekcije sa IC50 vrijednošću manjom od 50 μM koji ima sekvencu amino kiselina odabranu iz skupine koju čine
A peptide of claim 1 or 2 for use in the treatment of neurological diseases, in particular stroke, Parkinson's disease, Alzheimer's disease, multiple sklerosis the treatment of the WHIm-syndrom and rheumatoide arthritis; for the treatment of cancers, in particular cancers showing the CRCX receptor such as cancer of the liver, pancreas, prostate, or breast cancer; for the treatment of lack of mobilization, proliferation and migration of stem cells, T-cell activation as well as support of immunoblasts such as CTL/PD-1; for the treatment of antifibrosis; treatment or prevention of scars; for treatment of cardiologic disorders, in particular heart insufficiency; for the treatment of metabolic disorders, in particular diabetes. 
Peptid prema zahtjevu 1 ili 2 za upotrebu u liječenju neuroloških bolesti, posebice moždanog udara, Parkinsonove bolesti, Alzheimerove bolesti, multiple skleroze, u liječenju WHIm-sindroma i reumatoidnog artritisa; za liječenje više vrsta raka, posebice raka koji sadrži CRCX receptor kao što su rak jetre, gušterače, prostate, ili rak dojke; za liječenje nedostatka mobilizacije, proliferacije i migracije matičnih stanica, aktivacije T-stanica kao i potpora imunoblastima kao što je CTL/PD-1; za liječenje antifibroze; liječenje ili prevencije kod ožiljaka; za liječenje kardioloških poremećaja, posebice srčane inscufijencije; za liječenje metaboličkih poremećaja, posebice dijabetesa.
The peptide according to claim 1 or 2 for use in the treatment of disorders of hematopoiesis, in particular for support of the mobilization, proliferation and migration of stem cells; in the treatment of wounds, in particular wounds caused by burning; for the treatment of viral diseases, in particular infections with HIV-I, HIV-2, Cytomegalo virus, Herpes simplex virus (type 1 and 2), Varicella zoster virus, Hepatitis A and Hepatitis B virus, Influenza virus, Polio virus, Rhino virus, Rubella virus, Measles virus, Rabies virus, Rous sarcoma virus, Epstein-Barr Virus; and for the treatment of infections caused by bacteria and fungi, in particular Pseudomonas, Candida, S. aureus; for the treatment of infectious processes, abnormal infectious processes; treatment of growth disorders; treatment of neuronal diseases, disorders of the blood clotting cascade and hematopoiesis, vascular diseases, diseases of the immune system, and for improving wound and bone healing. 
Peptid prema zahtjevu 1 ili 2 za upotrebu u liječenju poremećaja hematopoeze, posebice za potporu mobilizacije, proliferacije i migracije matičnih stanica; u liječenju rana, posebice rana uzrokovanih spaljivanjem; za liječenje virusnih bolesti, naročito infekcija HIV-1, HIV-2, Cytomegalo virus, Herpes simplex virus (tip 1 i 2), Varicella zoster virus, Hepatitis A i Hepatitis B virus, Influenza virus, Polio virus, Rhino virus, Rubella virus, Measles virus, Rabies virus, Rous sarcoma virus, Epstein-Barr Virus; i za liječenje infekcija uzrokovanih bakterijama i gljivicama, posebice Pseudomonas, Candida, S. aureus; za liječenje infektivnih procesa, abnormalnih infektivnih procesa; liječenje kod poremećaja rasta; liječenje neuronalnih bolesti, poremećaja kaskade zgrušavanja krvi i hematopoeze, vaskularnih bolesti, bolesti imunološkog sustava, te za poboljšanje kod zacjeljivanja rana i kostiju.
The compound or pharmaceutically acceptable salt of claim 1, wherein said compound is selected from the group consisting of: -(3,4-dimethoxyphenyl)-2-(piperidin-4-ylethynyl)-7-(trifluoromethyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine; 
Spoj ili farmaceutski prihvatljiva sol prema zahtjevu 1, naznačen time što je navedeni spoj odabran iz skupine koja sadrži: -(3,4-dimetoksifenil)-2-(piperidin-4-iletinil)-7-(trifluorometil)-4,5,6,7-tetrahidropirazolo[1,5-a]pirimidin;
The compound or pharmaceutically effective salt of claim 33, wherein Ring A is: wherein X1, X2, and X3 are independently selected from the group consisting of -CH- and N; wherein X4 is -CH- or N; and wherein Z is piperazine, optionally bridged or substituted on a carbon by -CH3; hexahydropyrrolo[3,4]pyrrole; a five to seven member cyclic diamine; or -NH- substituted with a four to seven member cyclic amine; wherein X5 is -CH- or N; and wherein R is pyrazole; [1,2,4]oxadiazole optionally substituted by a -CH3 on a carbon of the oxadiazole; or -C(O)NH- substituted on its nitrogen by a four to seven member cyclic amine; 1,4-dimethylindazole-5-yl; 1,6-dimethylindazole-5-yl; 1-piperidinopyrazole; cyclohexene substituted with -NH2 at the 4' position; cyclohexene substituted with spiropiperidine at the 4' position; or 2-methoxypyridine-4-yl. 
Spoj ili farmaceutski učinkovita sol prema zahtjevu 33, naznačen time što prsten A je: pri čemu X1, X2, i X3 su neovisno odabrani iz skupine koju čine -CH- i N; pri čemu X4 je -CH- ili N; i pri čemu Z je piperazin, proizvoljno premošten ili supstituiran na ugljiku s -CH3; heksahidropirolo[3,4]pirolom; cikličkim diaminom s pet do sedam članova; ili -NH- supstituiran s cikličkim diaminom s četiri do sedam članova; pri čemu X5 je -CH- ili N; i pri čemu R je pirazol; [1,2,4]oksadiazol proizvoljno supstituiran s -CH3 na ugljiku u oksadiazolu; ili -C(O)NH- supstituiran na njegovom dušiku s četiri do sedam članim cikličkim aminom;,4-dimetilindazol-5-il; 1,6-dimetilindazol-5-il; 1-piperidinopirazol; cikloheksen supstituiran s -NH2 na položaju 4'; cikloheksen supstituiran s spiropiperidinom na položaju 4'; ili 2-metoksipiridin-4-il.
The compound of claim 33 having the absolute stereochemistry set forth in formula (V): or pharmaceutically acceptable salt thereof, wherein: R7a is H or F; wherein Ring A is: wherein X1, X2, and X3 are independently selected from the group consisting of -CH- and N; wherein X4 is -CH- or N; and wherein Z is piperazine, optionally bridged or substituted on a carbon by -CH3; hexahydropyrrolo[3,4]pyrrole; a five to seven member cyclic diamine; or -NH- substituted with a four to seven member cyclic amine; wherein X5 is -CH- or N; and wherein R is pyrazole; [1,2,4]oxadiazole optionally substituted by a -CH3 on a carbon of the oxadiazole; or -C(O)NH- substituted on its nitrogen by a four to seven member cyclic amine; 
Spoj prema zahtjevu 33 s apsolutnom stereokemijom navedenom u Formuli (V): ili njegova farmaceutski prihvatljiva sol, pri čemu: R7a je H ili F; pri čemu Prsten A je: pri čemu X1, X2, i X3 su neovisno odabrani iz skupine koju čine -CH- i N; pri čemu X4 je -CH- ili N; i pri čemu Z je piperazin, proizvoljno premošten ili supstituiran na ugljiku s -CH3; heksahidropirolo[3,4]pirol; ciklički amin od pet do sedam članova; ili -NH- supstituiran s cikličkim aminom od četiri do sedam članova; pri čemu X5 je -CH- ili N; i pri čemu R je pirazol; [1,2,4]oksadiazol proizvoljno supstituiran s -CH3 na ugljiku u oksadiazolu; ili -C(O)NH- supstituiran na njegovom dušiku s četiri do sedam članim cikličkim aminom;,4-dimetilindazol-5-il; 1,6-dimetilindazol-5-il;
contacting an amide solvate of the compound of formula (II): with an amine under conditions suitable for forming an amine salt of the compound of formula (II); and 
dovođenje u kontakt amid solvate spoja s formulom (II): s aminom pod uvjetima koji su pogodni za nastajanje soli amina spoja s formulom (II); i
The process according to Claim 3, wherein the compound of formula (I) is in the form of a hexahydrate. 
Postupak prema zahtjevu 3, naznačen time što je spoj s formulom (I) u obliku heksahidrata.
with acetic acid and water under conditions suitable for forming the compound of formula (V): 
s octenom kiselinom i vodom pod uvjetima koji su pogodni za nastajanje spoja s formulom (V):
contacting the amide solvate of the compound of formula (II) with an amine under conditions suitable for forming an amine salt of the compound of formula (II); and 
dovođenje u kontakt amid solvate spoja s formulom (II) s aminom pod uvjetima koji su pogodni za nastajanje soli amina spoja s formulom (II); i
A compound which is a triethylammonium salt of the compound of formula (II). 
Spoj naznačen time što je trietilamonijeva sol spoja s formulom (II).
Glass container according to claim 1, wherein the straight cylindrical section (51) extends from said lower end (71) of the thread turns (7) downwardly over a height (h4) of at least 5 mm. 
Stakleni spremnik u skladu s patentnim zahtjevom 1, naznačen time što se ravni valjkasti dio (51) pruža od navedenog donjeg kraja (71) zaokreta navoja (7) prema dolje po visini (h4) od najmanje 5 mm.
Glass container package comprising a glass container for storing non-pressurized beverages and a compressible stopper (9), wherein the stopper (9) has a plugging portion (91) of cylindrical form being insertable in the neck (1) of the container, wherein the container is according to claim 1. 
Ambalaža za stakleni spremnik, naznačena time što sadrži stakleni spremnik za spremanje nestlačenih napitaka i stlačivi čep (9), gdje čep (9) ima začepljujući dio (91) valjkastog oblika, kojeg se može umetnuti u grlo (1) spremnika, gdje je spremnik u skladu s patentnim zahtjevom 1.